Topic Listing for Memory Pharmaceuticals

Acquisition Warrant Personal Account Addition Collaborations Dependent Certain License Relationships
Additional Information Find Additional Terms Awards
Administration 2004 Plan Administration Espp
Administration Plan Affiliate
Aggregated Stock Option Exercises Last Year-end Values Aiver
Alternative Proposal Alzheimers Disease
Amended Restated 2003 Roche Collaboration Amended Restated 2004 Stock Incentive Plan
Amendment 2004 Plan Amendment Espp
Amendment Offer Letter Amendments Waivers
Amgen Agreement Amgen Inc 2005 Agreement
Amgen Inc Pde10 Inhibitor Program Animal Model Screening Processes
Annual Cash Bonus Annual Report
Antagonist Program Antagonists
Anthony Evnin Phd Antitakeover Provisions Place Entrench Management Team Delay Prevent
Appendix Appraisal Rights
Approval Issuance Sale Common Stock Approval Required
Arrant Assignment Registration Rights
Attend 2006 Annual Meeting Attend 2007 Annual Meeting
Attend Special Meeting Attendance Board Committee Meetings
Audit Committee Audit Committee Financial Expert
Audit Committee Report Authority Responsibilities
Axel Unterbeck Phd Background
Background Purpose Plan Base Salary
Basis Presentation Bayer In-license
Bayer Mem 1003 Bear Cost Soliciting Votes 2006 Annual Meeting
Bear Cost Soliciting Votes 2007 Annual Meeting Bear Cost Soliciting Votes Special Meeting
Because Not Intend Pay Dividends Benefit Investment Common Beneficial Owner
Beneficial Owners Beneficial Ownership Reporting Compliance
Benefit Plans Benefits Named Executive Officers Others
Bioinformatics Information Technology Systems Board Committee Fees
Board Director Designation Board Directors
Board Fees Board Recommend Vote
Bonus Bonuses
Business Business Activities Require Compliance Environmental Laws Violate Subject
Bylaws Cash Equivalents
Cautionary Statement Concerning Forward-looking Information Cautionary Statement Concerning Representations Warranties
Cceptance Central Nervous System Cognitive Function
Certain Federal Income Tax Consequences Reverse Split Certain Relationships Related Transactions
Certain Relationships Related Transactions Director Independence Certificate Amendment Incorporation Memory Pharmaceuticals Corp
Certificate Incorporation Change Control
Change Evergreen Provision Change Internal Control Over Financial Reporting
Change Vote Chief Executive Officer Compensation
Classification Hercules Debt Clinical Development
Clinical Trials Closing
Closings Cns Chemistry
Code Ethics Collaborations Development Agreements In-licenses
Collaborations Subject Risks Prevent Developing Commercializing Drug Candidates Collaborators Fail Obtain Regulatory Clearance Current Future Drug
Collaborators Products Subject Restrictions Withdrawal Market They Penalties Commitments
Committees Board Directors Common Stock
Common Stock Reserved Issuance 2004 Plan Common Stock Reserved Issuance Espp
Compared 2006 Compensation Committee
Compensation Committee Interlocks Insider Participation Compensation Committee Report
Compensation Directors Compensation Governance
Compensation Philosophy Compensation Philosophy Objectives
Competition Compliance Internal Revenue Code 162
Comprehensive Loss Concentrations Credit Risk
Conditions Closing Conditions Obligations
Conditions Purchasers Obligations Conduct Business Pending Closing
Consulting Agreements Control
Controls Procedures Corporate Information
Costs Associated Exit Disposal Activities Covenants
Creation Direct Financial Obligation Off-balance Sheet Arrangement Criteria Used Decision Apply Reverse Stock Split
Critical Accounting Policies Current Market Price
Current Therapies Treatment Alzheimers Disease Current Therapies Treatment Cias
Current Therapies Treatment Depression Current Therapies Treatment Schizophrenia
Currently Not Compliance Nasdaq Rules Regarding Minimum Bid David Lowe Phd
Debt Principal Repayments Due Delivery
Dennis Keane Departure Directors Certain Officers Election Appointment Compensatory
Departure Directors Principal Officers Election Appointment Depend Key Scientific Other Personnel Experienced Turnover Senior
Dependent Collaboration Partners Conduct Clinical Trials Manufacture Market Depression
Description Securities Determining Executive Compensation
Director Compensation 2006 Director Compensation 2007
Director Independence Director Qualifications Nomination Process
Directors Executive Officers Corporate Governance Directors Whose Terms Expire 2006 Class
Directors Whose Terms Expire 2007 Class Directors Whose Terms Expire 2007-class
Directors Whose Terms Expire 2008 Class Directors Whose Terms Expire 2008-class
Directors Whose Terms Expire 2009 Class Directors Whose Terms Expire 2009-class
Directors Whose Terms Expire 2010 Class Diseases Targeting Poorly Understood Increases Chances Failure
Disposition Stock Disposition Warrant Shares
Dissenters Rights Dissolution Liquidation Other Events
Dividend Policy Djustment Xercise Rice
Documents Incorporated Reference Drug Development Programs
Drug Discovery Programs Eadings
Effect Regulatory Requirements Executive Compensation Effect Stock Splits Recapitalizations Similar Transactions
Effects Certain Corporate Transactions Efinitions
Electronic Delivery Elements Executive Compensation Program
Eligibility Participate Espp Eligibility Receive Awards
Employee Stock Purchase Plan Employees
Employment Agreements Severance Payment Change Control Employment Arrangements
Entitled Vote 2006 Annual Meeting Entitled Vote 2007 Annual Meeting
Entitled Vote Special Meeting Entry Material Definitive Agreement
Equipment Financing Agreements Equipment Financing Arrangements
Equity Compensation Plan Information Estimates
Etc Evaluation Disclosure Controls Procedures
Event Everability
Exact Name Registrant Specified Charter Excess Securities
Executive Compensation Executive Employment Agreements
Executive Officers Executive Officers Directors Affiliates Ability Significantly Influence Matters
Exhibits Exhibits Financial Statement Schedules
Expect Continue Incur Substantial Losses Never Achieve Profitability Expenses
Explanatory Face Intense Competition Development Commercialization Drug Candidates
Face Risk Product Liability Claims Not Able Obtain Failure Obtain Regulatory Approval Foreign Jurisdictions Prevent Marketing
Fdca Federal Income Tax Consequences
Fees Billed Memory Pharmaceuticals Corp Kpmg Llp 2004 Fees Billed Memory Pharmaceuticals Corp Kpmg Llp 2005
Fees Billed Memory Pharmaceuticals Corp Kpmg Llp 2006 Fees Billed Memory Pharmaceuticals Corp Kpmg Llp 2007
Filing Date Final Prospectus
Financial Information Financial Statements Exhibits
Find Voting Results 2006 Annual Meeting Find Voting Results 2007 Annual Meeting
Foreign Regulatory Approval Form 10-k
Form Warrant Formula Option Grants Outside Directors
Fractional Shares Gardiner Smith
General Administrative Expense General Corporation Law State Delaware
General Release Claims General Research Tools
Government Regulation Grant Exercise Purchase Rights
Grants Plan-based Awards 2006 Great Point Entities
Hares Hat
Help Answer Questions Hercules Financing
Hoffmann-la Roche 2002 Agreement Hoffmann-la Roche Amended Restated 2003 Agreement
Hoffmann-la Roche Nicotinic Alpha-7 Agonist Program Hoffmann-la Roche Pde4 Inhibitor Program
Holder Householding
Householding Materials However
Http Wwwmemorypharmacom Identification Evaluation Director Candidates
Ights Impairment
Income Taxes Incorporation Reference
Increase Shares Authorized 775000 Ind Process
Indemnification Indemnified Party
Index Index Financial Statements
Industry Expert Information Concerning Executive Officers
Initial Public Offering Common Stock Inspector Elections Representative Adp-ics Vote Confidential
Insurance Risks Intellectual Property
Intend Announce Preliminary Voting Results 2005 Annual Meeting Interest Income Expense
Interests Certain Officers Directors Internet Whether Not Plan Attend 2007 Annual Meeting
Introduction Investment Act
Involved Lawsuits Protect Enforce Patents Collaborators Licensors Expensive James Sulat
Jonathan Fleming Joseph Donabauer
Jzaneen Lalani Lease Agreement
Life Science Product Limitations Effectiveness Controls
Long-term Equity Incentive Awards Long-term Incentives
Managements Annual Report Internal Control Over Financial Reporting Mandatory Registration
Manufacturing Manufacturing Capacity Depend Parties Supply Compounds Development Develop
Manufacturing Post-marketing Requirements Manufacturing Products Meet Applicable Regulatory Standards
Market Overview Marketable Securities
Material Agreements Material Effects Amendment
Mem 1003 Mem 1003 Treatment Alzheimers Disease
Mem 1003 Treatment Alzheimers Disease Bipolar Disorder Mem 1003 Treatment Bipolar Disorder
Mem 1414 Treatment Alzheimers Disease Mem 1917 Treatment Alzheimers Disease Depression
Mem 1917 Treatment Cns Disorders Mem 3454 Treatment Alzheimers Disease Cias
Mem 3454 Treatment Alzheimers Disease Schizophrenia Mem 63908 Treatment Alzheimers Disease Schizophrenia
Members Audit Committee Memory Pharmaceuticals
Memory Pharmaceuticals Corp Memory Pharmaceuticals Corp 100 Philips Parkway Montvale New
Memory Pharmaceuticals Drug Development Approach Memory Pharmaceuticals Strategy
Michael Meyers Mph Michael Smith
Miscellaneous Nasdaq
Nasdaq Approval Nasdaq Approval Requirement
Nda Process Need Additional Financing Difficult Obtain Failure Necessary Adversely
Net Loss Per Share New Accounting Pronouncement
New Accounting Pronouncements New Plan Benefits
Nicotinic Alpha-7 Agonist Program Mem 3454 63908 Nicotinic Alpha-7 Agonist Program Mem 3454 R4996 63908
Nicotinic Alpha-7 Agonists Nominations Committee
Nominees Standing Election Term Expiring 2008 Class Directors Nominees Standing Election Term Expiring 2009 Class Directors
Nominees Standing Election Term Expiring 2010-class Directors Nominees Standing Election Term Expiring 2011 Class Directors
Non-solicitation Not Able Succeed Business Model Seeking Enter Collaborations
Not Maintain Effectiveness Registration Statement Covering Resale Shares Not Maintain Effectiveness Registration Statements Covering Resale Certain
Notice Annual Meeting Stockholders Notice Special Meeting Stockholders
Notices Record Date Nps Allelix Corp 5-ht Antagonist Program
Number Authorized Shares Common Stock Obligations Purchasers
Offering Offerings
Option Grants Organization Business Overview
Other Benefits Other Business
Other Events Other Income Loss
Other Indications Other Material Contracts
Other Matters Other Regulatory Matters
Other Stock-based Awards Ovenants Ompany
Oversight Independent Auditors Overview
Oxford Oxford Entities
Part Participation
Parties Own Control Patents Proprietary Rights Infringed Technologies Party Offer
Party Offers Pde10 Inhibitor Program
Pde10 Inhibitors Pde4 Inhibitor Program Mem 1414 1917
Pde4 Inhibitors Performance Graph
Person Personal Benefits
Peter Young Physicians Patients Not Accept Product Candidates Unable Generate
Piggy-back Registration Placement Agent Agreement
Placement Agents Please Complete Sign Date Return Proxy Card Voting
Pledge Securities Policy Regarding Related Party Transactions
Policy Regarding Related Person Transactions Policy Regarding Review Approval Related Party Transactions
Potential Products Not Commercially Viable Collaborators Fail Obtain Power Attorney
Pre-approval Policies Procedures Preclinical Clinical Investigators Third-party Contract Research Organizations Consultants
Preclinical Safety Pharmacokinetics Preclinical Tests
Preferred Stock Preferred Stock Dividends Accretion
Principal Accountant Fees Services Principal Effects Approval Non-approval Proposal
Principal Investors Private Placement
Pro Forma Net Loss Per Share Procedure Effecting Reverse Split Exchange Stock Certificates
Procedures Administration Proceeds
Properties Property Equipment
Proposal Proposal Approval Amendment 2004 Employee Stock Purchase Plan
Proposal Approval Amendment 2004 Stock Incentive Plan Proposal Approval Amendment Amended Restated 2004 Employee Stock
Proposal Approval One-time Waiver 2004 Stock Incentive Plan Proposal Election Directors
Proposed Amendment 2004 Plan Provided Further
Provided However Provisions Applicable Restricted Stock Awards
Provisions Applicable Stock Options Proxy Solicited Board Directors
Proxy Statement Proxy Statement Pursuant Securities Exchange Act 1934 Amended
Purchase Agreement Purchase Price
Purchase Stock Purchasers
Purpose Purpose Background Reverse Split
Qualifications Director Candidates Quantitative Qualitative Disclosures Market Risk
Quarterly Operating Results Quorum Voting Requirements
R4996 Mem 63908 Treatment Alzheimers Disease Cias Ratification Appointment Kpmg Llp
Read Agree Terms Conditions Contained Herein Reasons Closing
Receiving Materials Recommendation Board Directors
Recommendations Nominations Committee Registrable Securities
Registration Registration Defaults
Registration Expenses Registration Period
Registration Rights Registration Statement
Regulation Disclosure Regulatory Approval
Rely Trade Secrets Other Confidential Information Maintain Proprietary Report Independent Registered Public Accounting Firm
Reporting Status Representations Warranties
Requirements Including Deadlines Submission Proxy Proposals Nomination Directors Research Development
Research Development Expense Research Development Expenses
Reservation Common Stock Restricted Cash
Restricted Stock Restrictions Transfer
Results Operations Financial Condition Retirement Plan
Revenue Revenue Recognition
Review Audited Financial Statements Review Other Financial Statements Disclosures
Risks Relating Intellectual Property Robert Kriebel
Roche Agreement Rule 13a-14 Securities Exchange Act 1934
Rule 4350 Sales Purchasers
Sarbanes-oxley Act 2002 Schedule 14a
Schedule Purchasers Closing Schizophrenia
Schizophrenia Cias Scientific Background
Sec Sec Documents
Secured Loan Agreement Contains Various Covenants Restrict Business Securities
Securities Act Securities Laws Disclosure Publicity
Securities Not Registered Securities Registered Pursuant Act
Security Ownership Certain Beneficial Owners Management Related Stockholder Seeking Stockholder Approval Issuance Excess Securities Institutional Investors
Selling Expenses Serve Inspector Elections
Shares Present Represented Conduct Business 2006 Annual Meeting Shares Present Represented Conduct Business 2007 Annual Meeting
Shares Present Represented Conduct Business Special Meeting Shares Subject Plan
Signatures Special Meeting
Standard Board Fees Option Grants Stanley Medical Research Institute Development Agreement
Stanley Medical Research Institute Mem 1003 Bipolar Disorder Stanley Medical Research Institute Smri Development Agreement
Stanley Medical Research Institute Smri Mem 1003 Bipolar Statements Operations
Stephen Murray Phd Stock Option Grants
Stock Option Grants Non-employee Directors Stock Options
Stock Price Subject Fluctuation Cause Investment Suffer Decline Stock Purchase Price
Stock-based Compensation Stockholder Approval
Stockholder Communication Board Directors Stockholder Recommendations Director Candidates
Stockholder Record Stockholders Find Information
Stockholders Proposals Stockholders Record
Structure Membership Submission Matters Vote Security Holders
Submitted Members Compensation Committee Substantial Sales Common Stock Price Decline
Summary 2004 Plan Summary Compensation Table
Summary Espp Summary Terms Securities Purchase Agreement
Summary Terms Warrants Superior Proposal
Table Contents Target Selection
Tax Effect Term Amendment Termination Plan
Term Termination 2004 Plan Termination Espp
Termination Material Definitive Agreement Terms Rights
Tony Scullion Top Form
Types Awards Unable Obtain Intellectual Property Protection Chemical Compounds Research
Unable Secure Requisite Approvals Drug Candidates Not Able Unmet Therapeutic Needs
Unrealized Loss Warrants Unregistered Sales Equity Securities
Valuation Hercules Put Option Vents
Vice Versa Vote
Vote Confidential Vote Important Accordingly Ask Complete Sign Date Return
Vote Mail Vote Person Special Meeting
Vote Required Approval Vote Telephone Over Internet
Votes Cast Return Proxy Card Votes Counted
Voting Agreements Walter Gilbert Phd
Warrant Liability Warrant Shares
Warrants What Business Voted 2006 Annual Meeting
What Business Voted 2007 Annual Meeting What Business Voted Special Meeting
What Deadline Submit Proposals Consideration 2008 Annual Meeting What Deadline Submitting Proposals Inclusion Memory Pharmaceuticals Proxy
What Difference Between Holding Shares Stockholder Record Beneficial What Happens Additional Matters Presented 2006 Annual Meeting
What Happens Additional Matters Presented 2007 Annual Meeting What Happens Additional Matters Presented Special Meeting
What Happens Nominee Unable Stand Election What Happens Proposal Not Approved
What Information Contained Proxy Statement What Questions Memory Pharmaceuticals Transfer Agent
What Quorum Not Present 2006 Annual Meeting What Quorum Not Present 2007 Annual Meeting
What Quorum Not Present Special Meeting What Receive Set Voting Materials
What Vote Required Approve Each Proposals What Vote Required Approve Proposal
What Voting Rights Holders Common Stock Withdrawal Espp Termination Employment
Wwwinvestordeliverycom Wwwmemorypharmacom
Wwwsecgov Xercise Arrant
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki